GARDEN GROVE, Calif., July 26, 2011 /PRNewswire/ — HYCOR
Biomedical, Inc., a leading manufacturer and marketer of in vitro
diagnostic products, today announced that it has signed an
agreement with Eurospital—a manufacturer of pharmaceutical
products, medical-surgical and diagnostic devices—to license
its tTG biomarker in all countries covered by the patent (excluding
the US and Canada) for its ability to diagnose celiac disease.
HYCOR today also announced that it has signed an agreement with
AXIS-SHIELD—a developer of in vitro diagnostic tests—to
license its anti-CCP biomarker for its ability to diagnose
rheumatoid arthritis (RA). Customers will have access to these
critical biomarkers from HYCOR in the coming weeks.
“We are pleased to offer HYCOR customers a tool to help
clinicians diagnose these devastating, chronic diseases,” said Dick
Aderman, CEO, HYCOR. “We look forward to continuing to expand our
diagnostic offerings, ensuring customers are able to meet the
ever-changing needs of the healthcare professionals they
serve.”
Celiac disease is a condition that damages the lining of the
small intestine and prevents it from absorbing nutrients properly,
leading to malnutrition. The symptoms of celiac disease vary from
one patient to the next, which poses challenges to healthcare
professionals in the accurate diagnosis of the disease. If left
untreated celiac disease can cause other complications, including
autoimmune disease, anemia and hypoglycemia, and, in some
instances, certain types of intestinal cancer.(i)
RA is a chronic autoimmune disease that leads to joint
inflammation, as well as inflammation of the surrounding tissue.
Early diagnosis of the disease, and early aggressive treatment, can
delay joint destruction and prevent symptoms from
worsening.(ii)
About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of
in vitro diagnostics products. Since it
‘/>”/>
